Each capsule contains: Mefenamic acid 500 mg.
Pharmacology: Pharmacokinetics: Mefenamic acid is absorbed from the gastrointestinal tract. Peak plasma concentrations occur about 2-4 hours after ingestion. The plasma elimination half-life is reported to be 2-4 hours. Mefenamic acid is extensively bound to plasma proteins. Mefenamic acid is distributed in to breast milk but the amount is considered by some authorities to be too small to be harmful to a breast-fed infant. Over 50% of a dose may be recovered in the urine as unchanged drug or conjugates of Mefenamic acid and its metabolites.
Indicated for mild to moderate pain including headache, dental pain, postoperative and postpartum pain, and dysmenorrhea, in musculoskeletal and joint disorders such as osteoarthritis and rheumatoid arthritis in menorrhagia, and in children with fever and juvenile idiopathic arthritis.
The usual dose by mouth is up to 500 mg capsule three times daily. A suggested dose for children over 6 months of age is 25 mg per kg body weight daily in divided doses. It is recommended that it should not be given for longer than 7 days at a time when used in the treatment of mild to moderate pain in adults and adolescents aged 14 years and over. Or as prescribed by the physician.
Mefenamic acid is contraindicated in patients with inflammatory bowel disease.
Absolute contraindications: Not to be given to those patients who have history of: Stroke; cerebrovascular accident, CVA.
Heart attack; Myocardial infarction, MI.
Coronary artery bypass graft, CABG.
Congestive heart failure (CHF) NYHA II-IV.
NSAIDs should not be given to patients with peptic ulceration and should be used with caution, if at all, in patients with a history of such disorders. To reduce the risk of gastrointestinal effects, NSAIDs may be taken with or after food or milk.
The common side effects occurring during therapy with NSAIDs are generally gastrointestinal disturbances such as gastrointestinal discomfort, nausea and diarrhea; these are usually mild and reversible but in some patients, peptic ulceration and severe gastrointestinal bleeding may occur. Treatment should be discontinued if diarrhea and rashes occur. Other effects reported include drowsiness, thrombocytopenia, occasionally hemolytic anemia and rarely aplastic anemia. Convulsions are a prominent feature of overdosage with Mefenamic acid.
Store at temperatures not exceeding 30°C.
M01AG01 - mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.